The role of ketogenic therapy in developmental disorders

Samia Taoulost; Natalie Rasgon; Casara Jean Ferretti; Eric Hollander

doi:10.1016/j.jpsychires.2023.03.025

The role of ketogenic therapy in developmental disorders

Samia Taoulost, Natalie Rasgon, Casara Jean Ferretti, Eric Hollander

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	307-309
Number of pages	3
Journal	Journal of Psychiatric Research
Volume	161
DOIs	https://doi.org/10.1016/j.jpsychires.2023.03.025
State	Published - May 2023

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jpsychires.2023.03.025

Cite this

@article{880e16018dc445549eeb95b34d3cc234,

title = "The role of ketogenic therapy in developmental disorders",

author = "Samia Taoulost and Natalie Rasgon and Ferretti, {Casara Jean} and Eric Hollander",

note = "Funding Information: Dr. Hollander reported receiving research grants from the US Department of Defense, the US Food and Drug Administration, GW Pharma, F. Hoffmann-La Roche Ltd; editorial stipends from Elsevier; and serving on scientific advisory boards for GW Pharma and F. Hoffmann- La Roche Ltd.",

year = "2023",

month = may,

doi = "10.1016/j.jpsychires.2023.03.025",

language = "English (US)",

volume = "161",

pages = "307--309",

journal = "Journal of Psychiatric Research",

issn = "0022-3956",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - The role of ketogenic therapy in developmental disorders

AU - Taoulost, Samia

AU - Rasgon, Natalie

AU - Ferretti, Casara Jean

AU - Hollander, Eric

N1 - Funding Information: Dr. Hollander reported receiving research grants from the US Department of Defense, the US Food and Drug Administration, GW Pharma, F. Hoffmann-La Roche Ltd; editorial stipends from Elsevier; and serving on scientific advisory boards for GW Pharma and F. Hoffmann- La Roche Ltd.

PY - 2023/5

Y1 - 2023/5

UR - http://www.scopus.com/inward/record.url?scp=85151032504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151032504&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2023.03.025

DO - 10.1016/j.jpsychires.2023.03.025

M3 - Article

C2 - 36989905

AN - SCOPUS:85151032504

SN - 0022-3956

VL - 161

SP - 307

EP - 309

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

ER -

The role of ketogenic therapy in developmental disorders

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this